Filing Analysis
Vivani Medical, Inc. filed an 8-K to provide a slide presentation used for investor updates at industry conferences. The filing is for regulatory purposes to ensure information distributed to the investment community is publicly available via the SEC.
📋 Key Facts
- The filing is pursuant to Item 7.01 (Regulation FD Disclosure).
- The company distributed a slide presentation to the investment community on August 17, 2026.
- The presentation is attached as Exhibit 99.1 and is not considered 'filed' for purposes of Section 18 of the Exchange Act.
Vivani Medical, Inc. filed an 8-K to announce its second quarter 2026 financial results and provide a business update via press release and slide presentation.
📋 Key Facts
- Reported date of event: August 13, 2026
- Released Q2 2026 financial results (Exhibit 99.1)
- Provided updated corporate slide presentation for investors (Exhibit 99.2)
Vivani Medical announced the successful completion of participant dosing in its Phase 1 clinical trial for NPM-139, a miniature, ultra long-acting semaglutide implant designed for chronic weight management.
📋 Key Facts
- Completed dosing of all participants in the SLIM-1 Phase 1 Trial.
- The trial evaluates NPM-139, an ultra long-acting semaglutide implant.
- Target indication is chronic weight management.
- Information was released via press release (Exhibit 99.1) under Item 7.01.
Vivani Medical, Inc. filed an 8-K to disclose a presentation made at the Emerging Growth Conference on July 15, 2026. The filing includes an update regarding the expected dosing timeline for the company's SLIM-1 product.
📋 Key Facts
- The Company presented at the Emerging Growth Conference in New York on July 15, 2026.
- CEO Dr. Adam Mendelsohn provided a slide presentation (Exhibit 99.1).
- First dosing of SLIM-1 is expected to take place in August 2026.
Vivani Medical, Inc. (via its subsidiary Cortigent) has entered into a definitive merger agreement with ClearOne, Inc., a Nasdaq-listed company. The transaction involves Vivani receiving 12.5 million shares of ClearOne common stock and includes a contingent $10M-$15M financing requirement to close the deal.
🚩 Red Flags
- Transaction is contingent upon the successful completion of a $10M-$15M financing via new equity issuance (Financing Units).
- Potential dilution for existing shareholders through the issuance of up to 5,000,000 new units.
- The merger's closing is dependent on ClearOne maintaining its continuous Nasdaq listing.
📋 Key Facts
- Vivani's subsidiary Cortigent will merge into a subsidiary of ClearOne, Inc.
- Vivani shareholders will receive 12,500,000 shares of ClearOne common stock as consideration.
- The transaction is contingent upon ClearOne raising $10M to $15M through a Form S-1 registration statement (Financing Units).
- The financing involves units consisting of one share and one warrant with an exercise price of $10.00 per share.
- Post-merger, the Board will consist of five members: four designated by Vivani and one by ClearOne majority holders.
- Vivani shareholders are subject to lock-up restrictions: 50% for one year and 50% for two years.
- The merger has a termination deadline of December 28, 2026.
Vivani Medical, Inc. reported results from its 2026 Annual Meeting of Stockholders and announced regulatory approval for a Phase 1 clinical trial in Australia.
🚩 Red Flags
- Significant increase in shares reserved under the Omnibus Incentive Plan (more than doubling the previous amount), which may lead to future dilution for existing shareholders.
📋 Key Facts
- Stockholders approved the adoption of the 2022 Amended Omnibus Incentive Plan.
- The 2022 Amended Plan increases reserved common stock from 10,033,333 to 21,033,333 shares (an increase of 11,000,000 shares).
- Six directors were elected to the Board to serve until the 2027 annual meeting.
- BPM LLP was ratified as the independent registered public accounting firm for fiscal year 2026.
- Received regulatory approval from Bellberry (Australia) to initiate a Phase 1 clinical trial of NPM-139, a semaglutide implant.
Vivani Medical, Inc. filed an 8-K to disclose a presentation being given by CEO Dr. Adam Mendelsohn at the Jefferies Global Healthcare Conference on June 4, 2026. The company provided the slide deck as an exhibit to ensure public dissemination of the information.
📋 Key Facts
- Presentation date: June 4, 2026, at 11:05 a.m. Eastern
- Event: Jefferies Global Healthcare Conference in New York
- Presenter: Dr. Adam Mendelsohn, Chief Executive Officer
- The slide presentation is attached as Exhibit 99.1 and posted on the company's website
Vivani Medical, Inc. reported its first quarter 2026 financial results and provided a business update. The filing also includes an updated corporate slide presentation for use in upcoming investor and industry conferences.
📋 Key Facts
- Reported Q1 2026 financial results on May 13, 2026
- Released an updated corporate slide presentation as Exhibit 99.2
- The report was filed under Item 2.02 (Results of Operations) and Item 7.01 (Regulation FD Disclosure)
Vivani Medical, Inc. filed a Form 8-K to announce its fourth quarter and full-year financial results. The filing includes a press release providing a business update alongside the financial data for the period ending December 31.
🚩 Red Flags
- Clerical discrepancy noted: The Item 2.02 text refers to 'Full Year 2024' results, while the Exhibit 9.01 description refers to 'Full Year 2025' results.
📋 Key Facts
- The report was filed on March 26, 2026, regarding events on the same date.
- The filing contains Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits).
- Exhibit 99.1 is a press release titled 'Vivani Medical Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update'.
- The company is listed on the Nasdaq Capital Market under the symbol VANI.
Vivani Medical, Inc. announced two simultaneous equity offerings on January 25, 2026: a $2.0 million private placement to an affiliate of the Board Chairman and a $2.5 million registered direct offering via ThinkEquity LLC. The combined gross proceeds total approximately $4.5 million.
🚩 Red Flags
- Related-party transaction: The private placement is with an entity affiliated with the Company's Board Chairman, Gregg Williams.
- Dilution risk: Significant issuance of new common stock through both private and registered offerings.
- Multiple 8-K items in a single filing (Item 1.01 and Item 3.02) indicating complex capital restructuring/fundraising.
📋 Key Facts
- Private Placement: 1,351,351 shares sold at $1.48 per share to an entity affiliated with Chairman Gregg Williams.
- Registered Offering: 1,689,200 shares via a registered direct offering through ThinkEquity LLC.
- Total gross proceeds from both offerings are approximately $4.5 million.
- Private placement was conducted under Rule 506 of Regulation D (unregistered).
- Registered offering involves a 7.0% cash fee to the agent and up to $125,000 in legal expense reimbursement.
- Directors and officers entered into 60-day lock-up agreements regarding the registered shares.
Vivani Medical, Inc. filed an 8-K to announce its third quarter 2025 financial results and provide a business update via press release and corporate slides.
📋 Key Facts
- Report date: November 13, 2025
- The filing includes the company's Q3 2025 financial results (Exhibit 99.1)
- The filing includes updated corporate slide presentations (Exhibit 99.2)
Vivani Medical, Inc. announced two simultaneous equity offerings on October 26, 2025: a $6.0 million private placement to an affiliate of the Board Chairman and a $9.7 million registered direct offering via ThinkEquity LLC. The combined gross proceeds total approximately $15.7 million.
🚩 Red Flags
- Related-party transaction: The private placement is with an entity affiliated with Chairman Gregg Williams.
- Significant dilution: Combined issuance of over 9.7 million new shares represents substantial potential dilution for existing shareholders.
- Multiple items in single filing (Item 1.01 and Item 3.02) indicating complex capital restructuring/fundraising.
📋 Key Facts
- Private Placement: 3,703,703 shares at $1.62 per share to an entity affiliated with Chairman Gregg Williams (Total: ~$6.0M).
- Registered Direct Offering: 6,000,000 shares via ThinkEquity LLC (Total gross proceeds: ~$9.7M before fees).
- The private placement was conducted under Rule 506 of Regulation D.
- Company agreed to pay a 7.0% cash fee to the Placement Agent and reimburse up to $125,000 in legal/expenses.
- Directors and officers entered into 60-day lock-up agreements regarding the registered offering.
Vivani Medical, Inc. has announced the temporary withdrawal of the previously scheduled record date (October 8, 2025) for the proposed spin-off of its subsidiary, Cortigent, Inc. The delay is attributed to administrative delays caused by a U.S. federal government shutdown.
🚩 Red Flags
- Delay in corporate restructuring (spin-off) can sometimes signal underlying administrative or regulatory hurdles, though here it is attributed to external macro factors.
📋 Key Facts
- The company was previously targeting October 8, 2025, as the record date for the Cortigent, Inc. spin-off.
- Cortigent, Inc. is a wholly-owned subsidiary focused on neuromodulation technology and brain implant devices.
- The delay is explicitly linked to the current shutdown of the U.S. federal government.
Vivani Medical, Inc. has announced the record date for the spin-off of its wholly-owned subsidiary, Cortigent, Inc., which specializes in neuromodulation brain implant devices.
📋 Key Facts
- Record date for the Cortigent, Inc. spin-off is set for October 8, 2025.
- Cortigent, Inc. is a wholly-owned subsidiary of Vivani Medical, Inc.
- Stockholders of record on October 8, 2025, will receive common stock in Cortigent upon completion of the spin-off.
- The distribution date and specific share dividend ratio are yet to be determined.
Vivani Medical, Inc. filed an 8-K to provide updated corporate slide presentations used for industry conferences and investor relations. The filing serves as a mechanism to distribute business updates via Exhibit 99.1.
📋 Key Facts
- The company is distributing updated corporate slides as of September 9, 2025.
- Slides are attached as Exhibit 99.1 and will also be posted on the 'Investors' section of the company website.
- Information in the slides is not considered 'filed' for purposes of Section 18 of the Exchange Act.
Vivani Medical, Inc. announced clinical development plans for NPM-139, an investigational semaglutide implant designed for chronic weight management in obese and overweight patients with comorbidities.
📋 Key Facts
- Announcement made on September 4, 2025.
- Focuses on NPM-139, a semaglutide implant.
- Target indication: Chronic weight management for obese/overweight patients with related comorbidities.
Vivani Medical, Inc. entered into a Share Purchase Agreement to issue 7,936,507 shares of common stock at $1.26 per share, aiming to raise approximately $10 million through July 15, 2026. The offering is being conducted via private placement to accredited investors and involves an entity affiliated with a company director.
🚩 Red Flags
- Related-party transaction: One of the purchasers is an entity affiliated with a company director.
- Dilution risk: Significant issuance of common stock (nearly 8 million shares) will dilute existing shareholders.
- Unregistered securities: Shares are being issued under a private placement exemption and are not registered under the Securities Act.
📋 Key Facts
- Total shares to be issued: 7,936,507 common stock shares.
- Price per share: $1.26 (matching the last reported sale price on Aug 11, 2025).
- Expected gross proceeds: Approximately $10.0 million.
- Timeline for closing: Multiple dates through July 15, 2026.
- Exemption used: Rule 506 of Regulation D (Section 4(a)(2)).
- No warrants or placement agent fees were incurred in this transaction.
Vivani Medical reported preliminary Q2 2025 financial results showing $6.8 million in cash and announced positive Phase 1 clinical data for its NPM-115 implant technology alongside promising preclinical weight loss data for a semaglutide implant (NPM-139).
🚩 Red Flags
- Preliminary financial data is unaudited and subject to material revision.
- The company's history of losses was noted in the forward-looking statements risk disclosures.
📋 Key Facts
- Preliminary Q2 2025 cash and cash equivalents: $6.8 million (unaudited, excluding restricted cash).
- Committed capital of $11.25 million expected through March 2026 via two equity purchase agreements from March/May 2025.
- LIBERATE-1 Phase 1 study for NPM-115 (exenatide implant) met primary objectives regarding safety, tolerability, and PK profile over 9 weeks; no serious adverse events reported.
- Preclinical data for NPM-139 (semaglutide implant) showed weight loss in rats for over 231 days from a single administration.
- Company is prioritizing the development of NPM-139 due to the massive commercial market for semaglutide products like Ozempic and Wegovy.
Vivani Medical, Inc. held its 2025 Annual Meeting of Stockholders on June 24, 2025. The meeting resulted in the election of six directors and the ratification of BPM LLP as the independent auditor.
🚩 Red Flags
- High number of 'Broker Non-Votes' (11,776,254 shares) across all proposals suggests significant portion of shares are held by institutions/brokers where the beneficial owner did not instruct how to vote on non-routine matters.
📋 Key Facts
- The 2025 Annual Meeting was held on June 24, 2025.
- A quorum was established with 37,097,099 shares represented (out of 59,243,903 total common stock shares).
- All six director nominees—Gregg Williams, Aaron Mendelsohn, Dean Baker, Alexandra Popoff, Adam Mendelsohn, and Daniel Bradbury—were elected to the Board.
- Stockholders ratified the appointment of BPM LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Stockholders approved executive compensation on a non-binding advisory basis.
Vivani Medical, Inc. filed an 8-K to provide updated corporate slide presentations via Regulation FD disclosure. The filing serves as a mechanism to distribute business updates to the investment community through industry conferences and the company's website.
📋 Key Facts
- The company is distributing updated corporate slides (Exhibit 99.1) as of June 17, 2025.
- Information is being provided to satisfy Regulation FD requirements for investor communications.
- The presentation material is intended for use at industry conferences and on the company's website.
Vivani Medical, Inc. announced the resignation of CFO Brigid Makes and the appointment of Anthony Baldor as the new CFO, Principal Financial Officer, and Principal Accounting Officer, effective June 15, 2025.
🚩 Red Flags
- Sudden departure of the Chief Financial Officer (effective in 5 days from filing date).
📋 Key Facts
- Brigid Makes resigned from her roles as CFO, PFO, and PAO on June 10, 2025; effective date is June 15, 2025.
- The company stated Ms. Makes' resignation was not due to any disagreement regarding operations, policies, or practices.
- Anthony Baldor appointed as CFO/PFO/PAO effective June 15, 2025.
- Baldor's compensation includes a $450,000 annual base salary and an option award for 600,000 shares of common stock vesting over four years.
- Baldor previously served as CFO at Diakonos Oncology Corp. and VP of Corporate Strategy at 4D Molecular Therapeutics, Inc.
Vivani Medical, Inc. announced the filing of a Form 10 registration statement for the planned spin-off of its wholly owned subsidiary, Cortigent, Inc. The goal is to make Cortigent an independent, publicly traded company on Nasdaq in 2025.
🚩 Red Flags
- Spin-offs can sometimes be used to isolate liabilities or separate high-growth assets from struggling parent companies, though this is not explicitly stated here.
📋 Key Facts
- Vivani Medical filed a Form 10 registration statement with the SEC.
- The spin-off involves 'Cortigent Neurostimulation Business' (Cortigent, Inc.).
- Cortigent is currently a wholly owned subsidiary of Vivani Medical.
- The transaction aims to make Cortigent an independent company listed on Nasdaq in 2025.
Vivani Medical entered into a Share Purchase Agreement with an entity owned by its Board Chairman, Gregg Williams, to issue 2,912,621 shares at $1.03 per share. The transaction is expected to raise approximately $3.0 million in gross proceeds through March 15, 2026.
🚩 Red Flags
- Related-party transaction: The buyer is the Chairman of the Board.
- Private placement: Shares are being issued via a private offering rather than a public offering.
📋 Key Facts
- Entered into a Share Purchase Agreement effective May 12, 2025.
- Purchaser is an entity beneficially owned by Gregg Williams, Chairman of the Board.
- Total shares to be issued: 2,912,621 common shares.
- Price per share: $1.03 (matching the last reported sale price).
- Expected gross proceeds: approximately $3.0 million by March 15, 2026.
- The placement will occur in two closing dates over the next ~10 months.
- Securities are being issued under Rule 506 of Regulation D (unregistered).
Vivani Medical, Inc. has amended its existing License and Supply Agreement with Okava Pharmaceuticals, Inc. to expand their collaboration into the veterinary space.
📋 Key Facts
- Amendment to License and Supply Agreement with Okava Pharmaceuticals, Inc.
- Expansion of OKV-119 development (long-acting GLP-1 therapy) to include canine/dog applications.
- Targeting metabolic health, weight management, diabetes, and longevity in dogs.
- The expansion was announced via a joint press release on April 15, 2025.
Vivani Medical, Inc. filed an 8-K to report its fourth quarter and full year 2024 financial results via a press release and provided updated corporate slide presentations for investors.
📋 Key Facts
- Reported Q4 and Full Year 2024 financial results on March 31, 2025.
- Issued a business update alongside the financial results (Exhibit 99.1).
- Distributed updated corporate slide presentations to the investment community (Exhibit 99.2).
Vivani Medical entered into a Share Purchase Agreement with an entity owned by Chairman Gregg Williams to issue 7,366,071 shares at $1.12 per share. The transaction is expected to raise approximately $8.25 million through January 2026 via five scheduled closings.
🚩 Red Flags
- Related-party transaction involving the Chairman of the Board
- Private placement via unregistered securities (Rule 506)
- Potential dilution for existing shareholders through issuance of over 7 million shares
📋 Key Facts
- Total shares to be issued: 7,366,071 common shares
- Price per share: $1.12 (matching the last reported sale price)
- Expected gross proceeds: ~$8.25 million
- Closing schedule: Five closings expected by January 15, 2026
- Purchaser: An entity beneficially owned by Gregg Williams, Chairman of the Board
- Exemption used: Rule 506 of Regulation D (Section 4(a)(2))
- No warrants or placement agent fees were incurred in this transaction
Vivani Medical, Inc. announced pre-clinical data for NPM-139, a subdermal semaglutide implant designed for chronic weight management in obese and overweight individuals.
📋 Key Facts
- Announcement date: March 26, 2025
- Product focus: NPM-139 (subdermal semaglutide implant)
- Target indication: Chronic weight management for obese and overweight individuals
- Data stage: Pre-clinical data released via press release
Vivani Medical announced a strategic plan to spin off its neurostimulation subsidiary, Cortigent, Inc., into an independent public company by mid-2025. Additionally, the company reported preliminary 2024 cash levels and achieved full enrollment in its LIBERATE-1 clinical trial for a GLP-1 implant.
🚩 Red Flags
- Preliminary financial information is unaudited and subject to material revision/adjustments.
- The spin-off is subject to significant conditions including tax-free status opinion, board approval, and regulatory/Nasdaq approval.
📋 Key Facts
- Planned spin-off of Cortigent, Inc. (wholly-owned subsidiary) via Form 10 registration statement, expected to complete by mid-2025 or Q3 2025.
- Preliminary cash and cash equivalents as of Dec 31, 2024: ~$18.4 million (unaudited).
- Achieved full enrollment in the LIBERATE-1 clinical trial for NPM-115 (GLP-1 implant) within four weeks.
- Top-line results from the LIBERATE-1 study are expected in mid-2025.
- Cortigent's Orion® Cortical Visual Prosthesis System has FDA Breakthrough Device designation.
Vivani Medical, Inc. issued an 8-K to announce its third quarter 2024 financial results and provide a general business update via press release and corporate slides.
📋 Key Facts
- Reported Third Quarter 2024 Financial Results on November 13, 2024.
- Issued a business update press release (Exhibit 99.1).
- Distributed updated corporate slide presentations to the investment community (Exhibit 99.2).
Vivani Medical, Inc. announced its upcoming participation in two industry conferences scheduled for late October 2024.
📋 Key Facts
- The company will present at the Partnership Opportunities in Drug Delivery (PODD) Event on October 29, 2024.
- The company will present at the ThinkEquity Conference on October 30, 2024.
Vivani Medical, Inc. announced it has received regulatory approval to initiate its first-in-human clinical trial (LIBERATE-1™) for its GLP-1 (exenatide) implant in Australia.
📋 Key Facts
- Regulatory approval received for LIBERATE-1™ clinical trial.
- Trial focuses on the Company's GLP-1 (exenatide) implant.
- Target population: Obese and overweight individuals.
- Location of trial: Australia.
Vivani Medical, Inc. announced its participation in the Emerging Growth Conference scheduled for September 25, 2024.
📋 Key Facts
- The company will present at the Emerging Growth Conference on September 25, 2024.
- A press release was issued on September 23, 2024, in connection with this announcement.
Vivani Medical, Inc. announced positive preclinical liver fat results regarding its GLP-1 (exenatide) implant. The company also confirmed that clinical development for the NPM-115 program is on track to begin in Q4 2024.
📋 Key Facts
- Announced positive preclinical liver fat results with the Company’s GLP-1 (exenatide) implant.
- Clinical development of the NPM-115 program in overweight and obese patients is scheduled to commence in Q4 2024.
- The announcement was made on September 4, 2024.
Vivani Medical, Inc. filed an 8-K to announce its second quarter 2024 financial results and provide a general business update via press release and corporate slides.
📋 Key Facts
- Reported date of event: August 13, 2024
- Released Q2 2024 financial results via Exhibit 99.1
- Distributed updated corporate slide presentations via Exhibit 99.2
- Filed under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure)
Vivani Medical, Inc. announced that it expects to initiate the first clinical study for its NPM-115 program in Q4 2024. The study will evaluate a 6-month GLP-1 implant designed to treat obesity or overweight patients with related comorbidities.
📋 Key Facts
- NPM-115 program is an investigational 6-month GLP-1 implant.
- Clinical study target start date: Fourth quarter of 2024.
- Study focus: Patients with obesity or overweight patients with related comorbidities.
Vivani Medical, Inc. reported the results of its 2024 Annual Meeting of Stockholders held on June 27, 2024. The meeting included the election of six directors and the ratification of BPM LLP as the independent auditor.
🚩 Red Flags
- High number of 'Broker Non-Votes' across all proposals (approx. 10.8M shares), indicating a significant portion of the shareholder base did not participate in voting via their brokers.
📋 Key Facts
- Annual Meeting held on June 27, 2024.
- Quorum was established with 35,232,561 of 54,978,465 shares represented (approx. 64% of total outstanding).
- All six director nominees were elected to serve until the 2025 Annual Meeting.
- Stockholders ratified BPM LLP as the independent registered public accounting firm for fiscal year ending December 31, 2024.
- Say-on-pay (non-binding advisory vote on executive compensation) was approved.
Vivani Medical, Inc. announced that the FDA has lifted a full clinical hold and cleared the company to initiate its LIBERATE-1 Phase 1 clinical trial for NPM-119 (exenatide), a six-month GLP-1 implant for type 2 diabetes.
📋 Key Facts
- FDA has lifted the full clinical hold on the Company's development program.
- The company is cleared to initiate the LIBERATE-1 Phase 1 clinical trial.
- The trial aims to assess safety, tolerability, and pharmacokinetics of NPM-119 (exenatide).
- NPM-119 is a miniature, six-month GLP-1 implant designed for type 2 diabetes treatment.
Vivani Medical, Inc. filed an 8-K to announce its first quarter 2024 financial results and provide a general business update via press release and corporate slides.
📋 Key Facts
- Reported Q1 2024 financial results on May 13, 2024.
- Issued a business update through Exhibit 99.1 (Press Release).
- Provided updated corporate slide presentations via Exhibit 99.2.
Vivani Medical, Inc. entered into an Open Market Sale Agreement with Jefferies LLC to facilitate the sale of up to $75.0 million in common stock via an at-the-market (ATM) offering.
🚩 Red Flags
- Significant potential for equity dilution due to the large $75M ATM offering relative to typical micro-cap market caps.
- ATM offerings are often used by cash-strapped companies to fund immediate operational expenses, potentially signaling liquidity needs.
📋 Key Facts
- Entered into Open Market Sale Agreement with Jefferies LLC on April 22, 2024.
- Aggregate offering price of up to $75.0 million in Common Stock.
- Jefferies will act as the sales agent for transactions including privately negotiated, block, or at-the-market (ATM) methods.
- The Company will pay Jefferies a commission of up to 3.0% of gross sales proceeds.
- A corresponding Form S-3 Registration Statement was filed on April 22, 2024.
Vivani Medical, Inc. issued a business update and reported its financial results for the fourth quarter and full year of 2023. The filing includes corporate presentation slides intended for investor relations.
🚩 Red Flags
- The filing is primarily a reporting event for past financial performance; specific net loss or cash burn figures are contained in the attached exhibits rather than the 8-K text itself.
📋 Key Facts
- Reported Q4 and Full Year 2023 financial results via press release (Exhibit 99.1).
- Provided a business update to the investment community.
- Released updated corporate slide presentations as of March 26, 2024 (Exhibit 99.2).
Vivani Medical, Inc. announced the appointment of Daniel Bradbury to its Board of Directors and Audit Committee. The move expands the Board from five to six members.
📋 Key Facts
- Daniel Bradbury appointed as Director on March 4, 2024.
- Board size expanded from five to six members.
- Mr. Bradbury will serve until the 2025 annual meeting of stockholders or earlier resignation/removal.
- Compensation includes a $35,000 annual cash retainer for Board service and $10,000 for Audit Committee service.
- Bradbury is the Executive Chairman and Co-Founder of Equillium, Inc. and former CEO of Amylin Pharmaceuticals.
Vivani Medical, Inc. entered into a Securities Purchase Agreement on March 1, 2024, to conduct a registered direct offering of common stock and warrants totaling approximately $15 million in gross proceeds.
🚩 Red Flags
- Significant dilution: The issuance of nearly 4 million shares plus warrants for up to another 4 million shares represents substantial potential dilution for existing shareholders.
- Warrant overhang: The 1:1 warrant ratio provides significant downward pressure on the stock price upon exercise.
📋 Key Facts
- Offering size: Approximately $15.0 million in gross proceeds (before fees).
- Securities issued: 3,947,368 shares of Common Stock and warrants to purchase up to 3,947,368 additional shares.
- Price per share/warrant: $3.80.
- Warrant terms: Exercise price of $3.80; exercisable immediately upon issuance; expires in three years.
- Placement Agent: Maxim Group LLC (7.0% cash fee + up to $65,000 legal reimbursement).
- Lock-up period: Directors and Officers are subject to a 90-day lock-up from the closing date.
Vivani Medical, Inc. issued a press release via Item 7.01 disclosing positive preclinical data for its NPM-115 weight loss implant and announced a strategic shift to prioritize its obesity portfolio.
📋 Key Facts
- Announced positive preclinical data for NPM-115 (twice-yearly exenatide implant) regarding weight loss effects.
- Claims NPM-115 results are comparable to Ozempic®/Wegovy®.
- Disclosed a strategic shift to prioritize the company's obesity portfolio, specifically mentioning NPM-139 as Semaglutide.
- Filed under Item 7.01 (Regulation FD Disclosure), meaning the information is furnished but not 'filed' for liability purposes under Section 18.
Vivani Medical, Inc. has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share. Following a period of non-compliance, the company's stock closed at or above $1.00 for 10 consecutive business days, resolving the delisting threat.
🚩 Red Flags
- Historical price volatility: The company recently faced a period of non-compliance due to the stock trading below $1.00.
📋 Key Facts
- The Company was previously notified by Nasdaq that it failed to meet the minimum bid price requirement of $1.00 per share between Nov 9, 2023, and Dec 21, 2023.
- As of January 9, 2024, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2).
- Compliance was achieved by maintaining a closing bid price of $1.00 or greater for 10 consecutive business days (Dec 22, 2023 – Jan 8, 2024).
- Nasdaq considers the delisting matter closed.